MarketInOut Stock Screener Log In | Sign Up
 

AbCellera Biologics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 08/03/2026 14:34
AbCellera Biologics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,743.69 mln
Float205 mln
Earnings Date08/05/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-0.7
Highly suspicious

1-Year Forecast

10.50
Transformational upside

Relative Strength

50 / 100
In line with market

Debt / Equity

0.15
Very low leverage

ROE

-14.69
Negative

Business Description

Founded in 2012 and based in Vancouver, Canada, AbCellera Biologics works to find and build new antibody treatments for patients who currently have few good options. The company has two drugs moving through clinical trials: one non-hormonal treatment for hot flashes and night sweats, and another targeting certain immune system disorders like atopic dermatitis. AbCellera works alongside major partners including Eli Lilly, AbbVie, and Biogen to advance its research and bring new medicines to market.

Key Fundamentals

EPS-0.48
ROE-14.69
RPS0.26
ROIC-21.01
ROA-10.64
EBITDA, mln-167
EV / EBITDA-7.42
EV / EBIT-6.26
Revenue, mln79.21
EV / Revenue15.64

Financial Strength

Altman Z-Score2.74
Piotroski F-Score 3 / 9
Beneish M-Score-0.7
Price to Intrinsic Value3.05
1-Year Target Price10.50
Short Ratio5.87
Short % of Float19.14

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.86% 93 / 100   
1 Month -28.24% 7 / 100   
2 Months 40.24% 95 / 100   
6 Months 60.77% 95 / 100   
1 Year 30.2% 75 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us